PRESENTATION · Mar 2025 · PDF

BBP-418 - MDA 2025 - Baseline Characteristics FORTIFY

PUBLICATION · Mar 2025 · PDF

Journal of the American College of Cardiology, Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy

PUBLICATION · Mar 2025 · PDF

Circulation, Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report from the Open-Label Extension of the ATTRibute-CM Trial

PUBLICATION · Mar 2025

Pediatric Neurology, Feasibility, Acceptability, and Reliability of Remote Motor Assessment in Children with Canavan Disease

PUBLICATION · Jan 2025

Human Gene Therapy, Urine N-Acetylaspartate Distinguishes Phenotypes in Canavan Disease

PRESENTATION · Dec 2024 · PDF

Acoramidis - AHA 2024 - Acoramidis reduces ACM and CVH: initial outcomes from the ATTRibute-CM open label extension study

PRESENTATION · Dec 2024 · PDF

Infigratinib - ISDS 2024 - Clinical Development Program Update

PRESENTATION · Dec 2024 · PDF

Encaleret - ADH1 - ASBMR 2024 Phase 2B Data over 24 Months

PRESENTATION · Dec 2024 · PDF

BBP-418 - WMS 2024 - FORTIFY Design

PRESENTATION · Dec 2024 · PDF

Canavan GTx BBP-812 - ESGCT 2024 - Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study